Arcus Biosciences, Inc.

Arcus trades at just $3.1B despite burning clinical-stage capital, with RSI at 57.5 suggesting neither oversold nor overbought conditions. The notable 14.24% short interest indicates meaningful skepticism about pipeline execution or valuation. Absent earnings (P/E n/a) and trading well below its 52-week high, this biotech faces binary outcomes tied entirely to drug development timelines and trial data. The short position warrants monitoring for potential squeeze dynamics, though fundamental catalysts—not technical triggers—will dictate directional moves. Valuation lacks traditional anchors; success hinges on pipeline advancement.